Ekso Bionics (NASDAQ:EKSO) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.16 and traded as high as $10.90. Ekso Bionics shares last traded at $10.15, with a volume of 44,832 shares traded.

Analyst Ratings Changes

A number of brokerages have weighed in on EKSO. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. Finally, Wall Street Zen raised Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $6.00.

Ekso Bionics Price Performance

The stock has a market cap of $36.13 million, a PE ratio of -1.98 and a beta of 0.79. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 0.09. The company’s fifty day moving average is $10.16 and its 200 day moving average is $7.02.

Insider Activity at Ekso Bionics

In other Ekso Bionics news, major shareholder Daniel Asher bought 15,540 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were acquired at an average price of $12.30 per share, with a total value of $191,142.00. Following the purchase, the insider owned 270,432 shares in the company, valued at approximately $3,326,313.60. The trade was a 6.10% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.00% of the company’s stock.

Institutional Trading of Ekso Bionics

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Ekso Bionics in the third quarter valued at about $57,000. Shay Capital LLC acquired a new position in shares of Ekso Bionics during the third quarter worth about $67,000. Citadel Advisors LLC purchased a new stake in shares of Ekso Bionics in the third quarter worth about $198,000. Geode Capital Management LLC grew its stake in shares of Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares in the last quarter. Finally, Consolidated Portfolio Review Corp acquired a new stake in shares of Ekso Bionics in the third quarter valued at about $333,000. 6.42% of the stock is currently owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.